Fibrinogen-transmitted hepatitis; a controlled study

Mainwaring, Rosser L.

doi:10.1001/jama.195.6.437

Search citation statements

Order By: Relevance

Paper Sections

Select...

Int J Gynaecol Obstet 161

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1971

1978

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fibrinogen concentrate was previously used to treat hypofibrinogenemia resulting from IFD. The Food and Drug Administration of the United States (4), however, has recently revoked the license for the manufacture and sale of fibrinogen (human) because of the unacceptably high incidence of hepatitis (6%-35%) following its use (9) and the availability of other products with lower risks. Antifibrinolytic agents, such as e-aminocaproic acid, are contrain-dicated in cases of IFD, since fatal fibrin deposition in the microvasculature can result (11).…”

Section: Int J Gynaecol Obstet 16mentioning

confidence: 99%

Consumption Coagulopathy Associated With Intrauterine Fetal Death: The Role of Heparin Therapy

Strauss

Ballard

Chamlian

1978

Intl J Gynecology & Obste

View full text Add to dashboard Cite

A gravida with intrauterine fetal death who developed progressive chronic consumption coagulopathy was treated with heparin. When serial fibrinogen levels fell below 100 mg% and the prothrombin time was significantly prolonged, intravenously injected heparin corrected hypofibrinogenemia. A safe delivery followed administration of oxytocin. The authors emphasize the infrequent need for heparin therapy in the majority of cases of the intrauterine fetal death syndrome. Therapeutic guidelines for its use in selected cases are reviewed.

show abstract

Section: Int J Gynaecol Obstet 16mentioning

confidence: 99%